Novo acquires Ziylo in quest for glucose-sensitive insulin

Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) acquired Ziylo Ltd. (Bristol, U.K.), giving the pharma a platform that could help it develop a glucose-responsive insulin.

Novo has identified glucose-sensitive insulin as an important innovative area for the company. The pharma is prioritizing innovative programs that substantially improve outcomes for patients and payers over those that provide incremental improvements over existing drugs (see "Mountain Climbing")...